However, Wang et al. recently found that in pMMR-MSI-L CRC tumors with low mutational burdens, the depletion of METTL3 or loss of METTL14 stimulates the secretion of CXCL9 and CXCL10 and induces METTL3/14-related STAT1 and IRF1 mRNA stability by YTHDF2, improving the response to anti-PD-1 therapy (Wang et al., 2020e). The gene discussed is METTL14; the disease is colorectal carcinoma.